Burning Rock Biotech Limited services

Burning Rock utilizes our own proprietary large-scale genomic dataset based on personalized analyses of Chinese cancer patients*, ntegrates the experience from multi-dimensional clinical/scientific research and published data, to provide a one-stop cancer genomic data solution for biopharma partners, aiming to speed up precision drug development and reduce the risks. Burning Rock provides effective biomarker clinical trial strategies for biopharma partners, including indication selection, patient screening and stratification, drug efficacy/mechanism exploration and recommendation of clinical study sites.

Burning Rock offers integrated central lab services for biopharma partners, from multimodal sample testing to data analysis, meeting drug developing requirement, with four industry-leading qualifications (CLIA, CAP, NCCL, and NMPA) and full spectra of diagnostic products. So far, we have provided central lab services with >50 clinical research studies for >30 pharmaceutical companies, covering clinical study sites globally.

Burning Rock proprietary database intelligent screening system screens reports, and regularly identifies patients with rare or specific genetic variants;

Burning Rock offers integrated companion diagnostic development services for biopharma partners to streamline the co-development and commercialization of targeted drugs and respective CDx （including registration testing, clinical evaluation and finally obtain registration certificates. Our US-based lab and R&D team provide additional services to promote drug and CDx co-development worldwide.

Cancer is a complicated disease caused by genetic variation. The genetic variation may deprive cells of the normal control function, leading to immortalization and cancer. And targeted drugs work well in cancer therapy, which can kill cancer cells that carry specific genes of variation. However, patients may differ from each other regarding the in vivo genetic variation. As a result, patients vary in the susceptibility and toxic and side effects to the same anti-cancer drugs. As the more inclusive “molecular typing” is proposed, more patients are able to accept targeted therapy, where physicians can custom therapeutic regimens for cancer patients varying in genetic variation to tap as many potentially available targeted drugs as possible and enhance therapeutic efficiency of the drugs. That’s how precision medicine works. Precision medicine needs a prerequisite - precision diagnosis.